Los puntos clave no están disponibles para este artículo en este momento.
Off-label prescribing is legal and common, but it is often done in the absence of adequate supporting data. Dr. Randall Stafford writes that although there is a strong rationale for greater FDA involvement in off-label use, it is moving toward relinquishing control in its new draft guidelines.
Randall S. Stafford (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: